Saturday 17 October 2026
Export ENVB’s income statement to Excel — free account
Enveric Biosciences, Inc.
ENVB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 93.5% and free cash flow fell 29.3%, each against the same quarter a year earlier.
1.38
0.01
−0.72%
Follow ENVB
Enveric Biosciences, Inc. (ENVB) P/E ratio
Enveric Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 933,794,466× (December 2015) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2020 | 14.7× | (9.44%) |
| Jun 2020 | 16.3× | (19.11%) |
| Mar 2020 | 20.1× | — |
| Dec 2019 | 0.0× | — |
| 19 more quarters | Free account |
Against its own ten years
Low 0.0×
High 933,794,466×
Ten-year median
0.0×
Current reading's percentile
87
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TRAW Traws Pharma, Inc. compare | n/m |
| ENVB Enveric Biosciences, Inc. | n/m |
| EVGN Evogene Ltd. compare | n/m |
| TCRT Alaunos Therapeutics, Inc. compare | n/m |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| IMNN Imunon, Inc. compare | n/m |
| ALZN Alzamend Neuro, Inc. compare | n/m |
| ACXP Acurx Pharmaceuticals, Inc. compare | n/m |
| LEXX Lexaria Bioscience Corp. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)